AR104751A1 - Derivado de urea o una sal de este aceptable desde el punto de vista farmacológico - Google Patents
Derivado de urea o una sal de este aceptable desde el punto de vista farmacológicoInfo
- Publication number
- AR104751A1 AR104751A1 ARP160101520A ARP160101520A AR104751A1 AR 104751 A1 AR104751 A1 AR 104751A1 AR P160101520 A ARP160101520 A AR P160101520A AR P160101520 A ARP160101520 A AR P160101520A AR 104751 A1 AR104751 A1 AR 104751A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituents
- optionally
- group
- aromatic heterocyclyl
- heterocyclyl group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Un derivado de urea o una sal de este aceptable desde el punto de vista farmacológico que tienen un efecto agonista de un receptor del péptido formilo tipo 1 (en adelante abreviado como FPRL1), una composición farmacéutica que contiene el derivado de urea o la sal de este aceptable desde el punto de vista farmacológico. Útiles para el tratamiento, la prevención o la supresión de enfermedades inflamatorias, enfermedades de las vías respiratorias crónicas, tipos de cáncer, septicemia, síntomas alérgicos, infección por retrovirus VIH, trastornos circulatorios, neuroinflamación, trastornos nerviosos, dolores, enfermedades prionósicas, amiloidosis, trastornos inmunitarios, y similares. Reivindicación 1: Un compuesto caracterizado porque está representado por la fórmula general (1) o una sal de este aceptable desde el punto de vista farmacológico: en donde, en la fórmula (1), Ar¹ es un grupo fenilo que tiene opcionalmente sustituyentes, un grupo heterociclilo aromático monocíclico que tiene opcionalmente sustituyentes, o un grupo heterociclilo aromático bicíclico que tiene 9 ó 10 átomos y tiene opcionalmente sustituyentes; Ar² es un grupo fenilo que tiene opcionalmente sustituyentes (siempre que cuando A es el resto de fórmula A1, el grupo fenilo cuyos sustituyentes son solamente átomos de halógeno sea excluido), un grupo heterociclilo aromático monocíclico que tiene opcionalmente sustituyentes, o un grupo heterociclilo aromático bicíclico que tiene 9 ó 10 átomos y tiene opcionalmente sustituyentes; A es un grupo seleccionado del grupo que consiste en A1), A2), A3), A4) y A5) del grupo de fórmulas (2); en donde R¹ y R² son independientemente un átomo de hidrógeno o un grupo C₁₋₆ alquilo que tiene opcionalmente sustituyentes, o R¹ y R² juntos forman un grupo C₂₋₆ alquileno; R³ es un átomo de hidrógeno o un grupo C₁₋₆ alquilo que tiene opcionalmente sustituyentes; X es un átomo de oxígeno, un átomo de azufre o SO₂; B es un grupo heterociclilo que tiene opcionalmente sustituyentes; y cada átomo de carbono marcado con un asterisco es un átomo de carbono asimétrico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015107227 | 2015-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR104751A1 true AR104751A1 (es) | 2017-08-09 |
Family
ID=56121143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160101520A AR104751A1 (es) | 2015-05-27 | 2016-05-26 | Derivado de urea o una sal de este aceptable desde el punto de vista farmacológico |
Country Status (18)
Country | Link |
---|---|
US (1) | US10525058B2 (es) |
EP (1) | EP3331884B1 (es) |
JP (1) | JP6746613B2 (es) |
KR (1) | KR20180006450A (es) |
CN (2) | CN107849049B (es) |
AR (1) | AR104751A1 (es) |
AU (1) | AU2016266190A1 (es) |
BR (1) | BR112017024966A2 (es) |
CA (1) | CA2987235A1 (es) |
CL (1) | CL2017002987A1 (es) |
CO (1) | CO2017013101A2 (es) |
EA (1) | EA201792382A1 (es) |
ES (1) | ES2814126T3 (es) |
IL (1) | IL255823A (es) |
MX (1) | MX2017015040A (es) |
PE (1) | PE20180234A1 (es) |
TW (1) | TW201702226A (es) |
WO (1) | WO2016189876A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6811241B2 (ja) | 2015-12-10 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | ピペリジノンホルミルペプチド受容体2およびホルミルペプチド受容体1アゴニスト |
JP2020015664A (ja) * | 2016-11-21 | 2020-01-30 | 宇部興産株式会社 | 含窒素多環式ヘテロ環誘導体 |
JP7098663B2 (ja) * | 2017-06-09 | 2022-07-11 | ブリストル-マイヤーズ スクイブ カンパニー | ピペリジノンホルミルペプチド2受容体アゴニスト |
CN110997653B (zh) * | 2017-06-09 | 2023-06-06 | 百时美施贵宝公司 | 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂 |
EP3634958B1 (en) * | 2017-06-09 | 2021-07-21 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
KR102623473B1 (ko) * | 2017-06-09 | 2024-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
DK3762380T3 (da) | 2018-03-05 | 2022-01-17 | Bristol Myers Squibb Co | Phenylpyrrolidinon-formylpeptid-2-receptoragonister |
AR114383A1 (es) * | 2018-03-09 | 2020-08-26 | Gruenenthal Gmbh | Piperidinas o piperidonas sustituidas con urea y fenilo |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US13001A (en) | 1855-06-05 | Method of composing- music | ||
CA2544983A1 (en) | 2003-11-07 | 2005-05-26 | Acadia Pharmaceuticals Inc. | Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation |
AR069650A1 (es) | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
JP4656674B2 (ja) | 2007-12-18 | 2011-03-23 | アクテリオン ファーマシューティカルズ リミテッド | アミノトリアゾール誘導体 |
JP5624130B2 (ja) | 2009-06-12 | 2014-11-12 | アクテリオンファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | Alx受容体アゴニストとしてのオキサゾール及びチアゾール誘導体 |
WO2011163502A1 (en) | 2010-06-24 | 2011-12-29 | Allergan, Inc. | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
CA2814826C (en) | 2010-11-17 | 2019-02-12 | Actelion Pharmaceuticals Ltd | Bridged spiro[2.4]heptane ester derivatives |
AU2011336973A1 (en) | 2010-12-03 | 2013-07-11 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity |
AU2011340103A1 (en) | 2010-12-07 | 2013-07-25 | Actelion Pharmaceuticals Ltd. | Hydroxylated aminotriazole derivatives as ALX receptor agonists |
MX2013006418A (es) | 2010-12-07 | 2013-07-15 | Actelion Pharmaceuticals Ltd | Derivados de oxazolil-metileter como agonistas del receptor de alx. |
AU2012214265A1 (en) | 2011-02-11 | 2013-09-05 | Allergan, Inc. | Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators |
US8653299B2 (en) | 2011-03-17 | 2014-02-18 | Allergan, Inc. | Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators |
UA114711C2 (uk) * | 2011-05-13 | 2017-07-25 | Еррей Біофарма Інк. | Сполуки піролідинілсечовини й піролідинілтіосечовини як інгібітори кінази trka |
CN104114164B (zh) | 2011-10-26 | 2016-11-16 | 阿勒根公司 | 作为甲酰肽受体样-1(fprl-1)受体调节剂的n-脲取代的氨基酸的酰胺衍生物 |
US9023865B2 (en) * | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
US8541577B2 (en) | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
MA37618B1 (fr) | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
ES2596521T3 (es) | 2012-05-16 | 2017-01-10 | Actelion Pharmaceuticals Ltd. | Derivados de espiro[2.4]heptano sustituidos con puente 1-(p-tolil)ciclopropilo como agonistas de receptor de ALX |
AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
JP6354757B2 (ja) | 2013-07-09 | 2018-07-11 | 小野薬品工業株式会社 | Alxr作動化合物 |
CN105377814B (zh) | 2013-07-16 | 2018-04-03 | 阿勒根公司 | 作为甲酰基肽受体调节剂的n‑脲取代的氨基酸的衍生物 |
AU2014292064B2 (en) | 2013-07-18 | 2018-07-05 | Idorsia Pharmaceuticals Ltd | Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
NZ720508A (en) * | 2013-11-28 | 2019-03-29 | Kyorin Seiyaku Kk | Urea derivative or pharmacologically acceptable salt thereof |
US10136420B2 (en) * | 2014-09-26 | 2018-11-20 | Nokia Of America Corporation | Methods and systems for signaling dynamic network assisted information to a user equipment |
WO2016095089A1 (en) | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
-
2016
- 2016-05-26 KR KR1020177036827A patent/KR20180006450A/ko not_active Application Discontinuation
- 2016-05-26 TW TW105116494A patent/TW201702226A/zh unknown
- 2016-05-26 MX MX2017015040A patent/MX2017015040A/es unknown
- 2016-05-26 CA CA2987235A patent/CA2987235A1/en not_active Abandoned
- 2016-05-26 PE PE2017002476A patent/PE20180234A1/es unknown
- 2016-05-26 CN CN201680041960.XA patent/CN107849049B/zh not_active Expired - Fee Related
- 2016-05-26 US US15/576,350 patent/US10525058B2/en not_active Expired - Fee Related
- 2016-05-26 CN CN202110177501.7A patent/CN113185452A/zh active Pending
- 2016-05-26 AR ARP160101520A patent/AR104751A1/es unknown
- 2016-05-26 JP JP2017560628A patent/JP6746613B2/ja not_active Expired - Fee Related
- 2016-05-26 AU AU2016266190A patent/AU2016266190A1/en not_active Abandoned
- 2016-05-26 EA EA201792382A patent/EA201792382A1/ru unknown
- 2016-05-26 ES ES16729077T patent/ES2814126T3/es active Active
- 2016-05-26 BR BR112017024966A patent/BR112017024966A2/pt not_active Application Discontinuation
- 2016-05-26 WO PCT/JP2016/002557 patent/WO2016189876A1/en active Application Filing
- 2016-05-26 EP EP16729077.4A patent/EP3331884B1/en active Active
-
2017
- 2017-11-21 IL IL255823A patent/IL255823A/en unknown
- 2017-11-24 CL CL2017002987A patent/CL2017002987A1/es unknown
- 2017-12-20 CO CONC2017/0013101A patent/CO2017013101A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2017015040A (es) | 2018-08-14 |
IL255823A (en) | 2018-01-31 |
BR112017024966A2 (pt) | 2018-08-07 |
CN107849049B (zh) | 2021-03-16 |
WO2016189876A1 (en) | 2016-12-01 |
EP3331884A1 (en) | 2018-06-13 |
JP2018521005A (ja) | 2018-08-02 |
ES2814126T3 (es) | 2021-03-26 |
PE20180234A1 (es) | 2018-01-31 |
EP3331884B1 (en) | 2020-06-17 |
KR20180006450A (ko) | 2018-01-17 |
US20180207153A1 (en) | 2018-07-26 |
CN113185452A (zh) | 2021-07-30 |
EA201792382A1 (ru) | 2018-04-30 |
JP6746613B2 (ja) | 2020-08-26 |
CL2017002987A1 (es) | 2018-05-25 |
CN107849049A (zh) | 2018-03-27 |
CO2017013101A2 (es) | 2018-05-21 |
AU2016266190A1 (en) | 2018-01-18 |
TW201702226A (zh) | 2017-01-16 |
CA2987235A1 (en) | 2016-12-01 |
US10525058B2 (en) | 2020-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR104751A1 (es) | Derivado de urea o una sal de este aceptable desde el punto de vista farmacológico | |
DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
PE20212077A1 (es) | Nuevos compuestos sulfonamida de carboxamida | |
UY36056A (es) | “compuestos de heteroarilo o arilo bicíclicos fusionados “. | |
AR103251A1 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
CL2016001283A1 (es) | Derivado de urea o sal farmacológicamente aceptable del mismo | |
BR112015018509A2 (pt) | compostos de imidazo piridina | |
MD3416631T2 (ro) | Agenți terapeutici pentru bolile neurodegenerative | |
CL2019001041A1 (es) | Compuestos terapéuticos y métodos para utilizarlos. | |
BR112016017781A2 (pt) | Compostos de pirazolona e usos dos mesmos | |
CY1124413T1 (el) | Ανταγωνιστες του υποδοχεα cgrp | |
CY1121345T1 (el) | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης | |
EA201692298A1 (ru) | Производные карбоксамидов | |
EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
CY1122375T1 (el) | Συμπυκνωμενα με τετραϋδροφουρανιο αμινοϋδροθειαζινικα αναλογα τα οποια ειναι χρησιμα στη θεραπεια της νοσου toy alzheimer | |
EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
CY1123185T1 (el) | Παραγωγα ινδολιου | |
CY1125090T1 (el) | Ενωση γουανιδινης αντικαταστασης | |
AR101976A1 (es) | Derivados de piridin-2(1h)-on quinolinona como inhibidores de isocitrato deshidrogenasa mutante | |
EA201790020A1 (ru) | Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний | |
AR100646A1 (es) | Derivado de piridina | |
AR118302A1 (es) | Compuestos disulfuro y composiciones que comprenden los mismos para tratar hipertensión o fallo cardíaco | |
EA201600411A1 (ru) | Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |